 | | Vol. 10.08 – 18 March, 2024 |
| |
|
|
| Investigators showed that HAPLN1 in the dermal extracellular matrix was sufficient to maintain the integrity of melanoma-associated blood vessels, as indicated by increased collagen and VE-cadherin expression.
[Nature Aging] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| | DERMAL STEM CELLS & TISSUE REGENERATION |
|
|
|
| In a 3D organotypic human epidermis model, loss of dolichyl-phosphate mannosyltransferase subunit 1 (DPM1) caused impaired differentiation with abnormally increased cornification, reduced thickness of non-corneal layers, and formation of intercellular gaps in the epidermis.
[Journal Of Cell Biology] |
|
|
|
| Scientists demonstrated that after SPRY1 knockout in epidermal keratinocytes, melanocyte stem cells in the hair follicle exit the niche without depleting the pool of these cells.
[Journal Of Investigative Dermatology] |
|
|
|
| Researchers employed qRT-PCR and fluorescence in situ hybridization to evaluate miR-6785-5p in psoriatic keratinocytes and conducted a microRNA microarray for identifying differentially expressed miRNAs in patient serum exosomes.
[Inflammation] |
| |
|
|
| The authors showed that miR-579-3p was specifically deregulated in BRAF-mutant melanomas and that its expression levels mirrored those of microphthalmia-associated transcription factor (MITF).
[Cell Death & Disease] |
|
|
|
| Investigators explored extracellular galectin-3 expression in human melanoma tissues as well as murine melanoma models to examine its causal role in metastatic behavior.
[Journal Of Investigative Dermatology] |
|  |
|
|
|
| The authors discuss research progress on lipid metabolism in melanoma, and emphasize the dynamic ability of metabolism during tumorigenesis as a target for improving response to different therapies and for overcoming drug resistance in melanoma.
[Biochemical Pharmacology] |
|
|
|
|
| A team of investigators from the UCLA Health and the University of Arkansas as awarded a $3.2 million grant from the National Institutes of Health to identify new ways to prevent and overcome treatment resistance to targeted therapy in patients with all sub-types of cutaneous melanoma.
[UCLA Health] |
|
|
|
|
| April 24 – 26, 2024
Vienna, Austria |
|
|
|
|
|
| | abbvie – Irvine, California, United States |
|
|
|
| | University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Office of Women’s Health Grant Program – Jefferson, Arkansas, United States |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
| | Brown University – Providence, Rhode Island, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
